Valuation: XOMA Royalty Corporation

Market Cap 529M 463M 427M 398M 751M 49.98B 764M 5.12B 1.99B 24.66B 1.99B 1.94B 85.92B P/E 2026 *
53.6x
P/E 2027 * -843x
Enterprise Value 529M 463M 427M 398M 751M 49.98B 764M 5.12B 1.99B 24.66B 1.99B 1.94B 85.92B EV / Sales 2026 *
8.7x
EV / Sales 2027 * 10.1x
Free-Float
97.66%
Yield 2026 *
-
Yield 2027 * -
1 day+0.17%
1 week+0.69%
Current month+1.27%
1 month+1.32%
3 months+39.64%
6 months+61.34%
Current year+58.86%
1 week 41.81
Extreme 41.81
42.5
1 month 40.76
Extreme 40.76
42.5
Current year 22.29
Extreme 22.29
42.81
1 year 22.29
Extreme 22.29
42.81
3 years 13.48
Extreme 13.48
42.81
5 years 13.48
Extreme 13.48
42.81
10 years 3.96
Extreme 3.96
46.32
Manager TitleAgeSince
Chief Executive Officer 51 2022-12-31
Director of Finance/CFO 42 2026-01-11
Chief Investment Officer 45 2023-01-02
Director TitleAgeSince
Chairman 70 2024-01-06
Director/Board Member 72 2012-12-12
Director/Board Member 52 2017-02-15
Date Insider Type Main position Quantity % Market Cap.
05-20Free

Director

3,586 0.0296%
05-20Free

Chairman

3,586 0.0296%
05-20Free

Director

3,586 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
+0.33%+0.69%+67.62%+123.61% 529M
+0.21%-4.89%+46.86%+64.44% 561M
-1.74%-1.74%-5.35%-15.77% 366M
+1.38%+1.30%-37.89%-43.57% 78.6M
-1.89%-5.88%-24.36%+11.83% 51.82M
Average -0.37%-1.56%+9.37%+28.11% 317.2M
Weighted average by Cap. -0.26%-1.52%+35.21%+58.59%

Financials

2026 *2027 *
Net sales 60.73M 53.16M 49.07M 45.77M 86.25M 5.74B 87.79M 589M 229M 2.83B 228M 223M 9.87B 52.5M 45.95M 42.42M 39.57M 74.56M 4.96B 75.89M 509M 198M 2.45B 197M 193M 8.53B
Net income 15.03M 13.16M 12.15M 11.33M 21.35M 1.42B 21.73M 146M 56.57M 701M 56.48M 55.22M 2.44B -900K -788K -727K -678K -1.28M -85.1M -1.3M -8.72M -3.39M -41.99M -3.38M -3.31M -146M
Net Debt - -
Logo XOMA Royalty Corporation
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Employees
14
Date Price Change Volume
26-06-30 US$42.25 +0.23% 65,348
26-06-29 US$42.15 0.00% 368,083
26-06-26 US$42.15 -0.12% 439,305
26-06-25 US$42.20 +0.12% 122,047
26-06-24 US$42.15 +0.48% 164,691
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
42.15USD
Average target price
39.00USD
Spread / Average Target
-7.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XOMA Stock